Metastatic Gastric Adenocarcinoma — Apatinib Plus Irinotecan as Second-line Treatment in AGC or EGJA
Citation(s)
A Prospective, Multicenter Clinical Study of Apatinib Plus Irinotecan as Second-line Treatment in Locally Advanced or Metastatic Gastric or Gastroesophageal Junctional Adenocarcinoma